Jan 29 (Reuters) - Inhibikase Therapeutics IKT.O said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating and walking in a mid-stage study.
Shares of the drug developer tumbled nearly 22% to $2.19 in extended trading.
However, the drug, risvodetinib, was found to be safe and well tolerated, meeting the main goal of the study, the company said.
The study enrolled 126 people with untreated Parkinson's disease, a progressive neurological disorder that impairs the brain's nerve cells and affects the production of dopamine, a neurotransmitter that regulates functions such as memory, movement and mood.
It is estimated that 1 million people in the U.S. live with the incurable condition.
The established standard of care for the disease, levodopa, acts as a replacement agent for dopamine.
Last month, AbbVie's ABBV.N experimental drug, tavapadon, helped significantly improve patients' ability to carry out daily tasks in a late-stage study.
Inhibikase said it will consider strategic options for risvodetinib and will focus on its lead drug candidate, which is being developed to treat a rare condition that causes high blood pressure in the lungs.
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。